Cargando…

Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events

INTRODUCTION: Duodenal Mucosal Resurfacing (DMR) is an endoscopic ablation technique aimed at improving glycaemia and metabolic health in patients with type 2 diabetes mellitus (T2DM). DMR has an insulin sensitizing effect in patients with T2DM. Reducing hyperinsulinemia can improve cardiovascular h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meiring, S., Busch, C. B. E., van Baar, A. C. G., Hemke, R., Holleman, F., Nieuwdorp, M., Bergman, J. J. G. H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503196/ https://www.ncbi.nlm.nih.gov/pubmed/36138441 http://dx.doi.org/10.1186/s12933-022-01628-z

Ejemplares similares

Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
por: Meiring, Suzanne, et al.
Publicado: (2022)

Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?
por: van Baar, Annieke C G, et al.
Publicado: (2021)

A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study
por: Meiring, Suzanne, et al.
Publicado: (2022)

Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolites
por: van Baar, Annieke C G, et al.
Publicado: (2018)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Common Genetic Variation in GLP1R and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects: A pilot study
por: Sathananthan, Airani, et al.
Publicado: (2010)

Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study
por: van Baar, Annieke C G, et al.
Publicado: (2020)

ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022)

The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
por: Liu, Jhih-Syuan, et al.
Publicado: (2023)

Elevated Circulating Fetuin-B Levels Are Associated with Insulin Resistance and Reduced by GLP-1RA in Newly Diagnosed PCOS Women
por: Mokou, Mani, et al.
Publicado: (2020)

LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin
por: Hoog, Meredith, et al.
Publicado: (2022)

Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study
por: Koopen, Annefleur, et al.
Publicado: (2022)

Diabetes-Associated Common Genetic Variation and Its Association With GLP-1 Concentrations and Response to Exogenous GLP-1
por: Smushkin, Galina, et al.
Publicado: (2012)

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
por: Blonde, Lawrence, et al.
Publicado: (2020)

Fixed-Ratio combinations (Basal Insulin Plus GLP-1RA) in Type 2 diabetes. An analytical review of pivotal clinical trials
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2023)

Intra-islet glucagon confers β-cell glucose competence for first-phase insulin secretion and favors GLP-1R stimulation by exogenous glucagon
por: Cabrera, Over, et al.
Publicado: (2021)

Simultaneous analyses of carbohydrate-mediated serum GLP-1 and GLP-2 and duodenal receptor expression in children with and without celiac disease
por: Rachmiel, Marianna, et al.
Publicado: (2019)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy
por: Jensterle, Mojca, et al.
Publicado: (2022)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway
por: Wei, Liufeng, et al.
Publicado: (2022)

Knock-Down of IL-1Ra in Obese Mice Decreases Liver Inflammation and Improves Insulin Sensitivity
por: Franck, Niclas, et al.
Publicado: (2014)

Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2017)

Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia
por: Suastika, Ketut, et al.
Publicado: (2022)

Application of radiofrequency ablation in duodenal mucosal reconstruction
por: Li, Zhengqi, et al.
Publicado: (2023)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
por: Jensterle, Mojca, et al.
Publicado: (2022)

Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans
por: Heni, Martin, et al.
Publicado: (2015)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitus
por: van Baar, Annieke C.G., et al.
Publicado: (2020)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Duodenal Endoluminal Barrier Sleeve Alters Gut Microbiota of ZDF rats
por: Kim, Teayoun, et al.
Publicado: (2016)

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
por: Desouza, Cyrus, et al.
Publicado: (2020)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients
por: Hu, Xiaolei, et al.
Publicado: (2017)

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)

Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
por: Zheng, Dan, et al.
Publicado: (2009)

Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
por: Tofé, Santiago, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cueik5br058rf9t5iu5ed891tu